Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Capsules
Patent
1995-06-07
1997-09-09
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Capsules
424455, 424456, 514946, A61K 948
Patent
active
056653867
ABSTRACT:
A method for increasing bioavailability and reducing inter- and intra-individual variability of an orally administered hydrophobic pharmaceutical compound, which comprises orally administering the pharmaceutical compound to a mammal in need of treatment with the compound concurrently with an essential oil or essential oil component in an amount sufficient to provide bioavailability of the compound in the presence of the essential oil or essential oil component greater than bioavailability of the compound in the absence of the essential oil or essential oil component, wherein the essential oil or essential oil component has an activity of at least 10% inhibition at a concentration of 0.01 wt. % or less in an assay that measures conversion of cyclosporine to hydroxylated products using an assay system containing 250 .mu.g rat liver microsomes, 1 .mu.M cyclosporine, and 1 mM reduced nicotinamide adenine dinucleotide phosphate (NADPH) in 1 ml of 0.1M sodium phosphate buffer, pH 7.4.
REFERENCES:
patent: 4822816 (1989-04-01), Markham
patent: 4849227 (1989-07-01), Cho
patent: 4944949 (1990-07-01), Story et al.
patent: 4968716 (1990-11-01), Markham
patent: 5070085 (1991-12-01), Markham
patent: 5156842 (1992-10-01), Mulligan
patent: 5179122 (1993-01-01), Greene et al.
patent: 5284657 (1994-02-01), Lu et al.
patent: 5332747 (1994-07-01), Van Dyke
patent: 5350756 (1994-09-01), Smith
patent: 5409690 (1995-04-01), Howell et al.
patent: 5422350 (1995-06-01), Woolf
patent: 5424289 (1995-06-01), Yang et al.
patent: 5436243 (1995-07-01), Sachs et al.
patent: 5455286 (1995-10-01), Amidon et al.
patent: 5466696 (1995-11-01), Woolf
Bonkvosky et al., Cytochrome P.sub.450 of Small Intestinal Epithelial Cells, Gastroenterology, 88:458-467 (1985).
Bradford, A Rapid and Sensitive Method for the Quantification of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding, Analytical Biochemistry, 72:248-254 (1976).
Hait et al., Terfenadine (Seldane.RTM.): A New Drug for Restoring Sensitivity to Multidrug Resistant Cancer Cells, Bioch. Pharm., 45(2):401-406 (1993).
Hsing et al., The Function of Gp170, the Multidrug-Resistance Gene Product, in the Brush Border of Rat Intestinal Mucosa, Gastroenterology, 102:879-885 (1992).
Kronbach et al., Cyclosporine Metabolism in Human Liver: Identification of a Cytochrome P-450III Gene Family as the Major Cyclosporine-Metabolizing Enzume Explains Interactions of Cyslosporine with Other Drugs, Clin. Pharmacol. Ther., 43(6)630-635 (1988).
Nash, The Colorimetric Estimation of Formaldehyde by Means of the Hantzsch Reaction, Biochem., 55:416-421 (1953).
Nielsen et al., P-Glycoprotein as Multidrug Transporter: A Critical Review of Current Multidrug Resistant Cell Lines, Chimica et Biophysica Acta., 1139:169-183 (1992).
Omura et al., The Carbon Monoxide-Binding Pigment of Liver Microsomes, J. Biol. Chem., 239(7):2370-2378 (1964).
Schmiedlin et al., Cultured Adult Rat Jejunal Explants as a Model for Studying Regulation of CYP3A, Biochemical Pharmacology, 46(5):905-918 (1993).
Watkins et al., Identification of Glucocorticoid-Inducible Cytochromes P-450 in the Intestinal Mucosa of Rats and Man, J. Clin. Invest., 80:1029-1036 (1987).
Wrighton et al., Demonstration in Multiple Species of Inducible Hepatic Cytochromes P-450 and Their mRNAs Related to the Glucorcorticoid-Inducible Cytochrome P-450 of the Rat, Molecular Pharmacology, 28:312-321 (1985).
Yoda et al., On the Reversibility of Binding of Cardiotonic Steroids to a Partially Purified (Na+K)-Activated Adenosinetriphosphatase from Beef Brain, Biochemical and Phisical Reserch Communications, 40(4):880-887 (1970).
Adams, M.W., d-Alpha Tocopheryl Polyethylene glycol 1000 Succinate (Eastman vitamin E TPGS) as an Emulsifier and Bioenhancer for Drugs and Lipophilic Compounds, 6th International Conference on Pharmaceutical technology, Paris, 2-4 Jun., 1992.
Albengres et al., "Cyclosporin and Ketoconazole, Drug Interaction or Therapeutic Association?", International Journal of Clinical Pharmacology et al., 30(12): 555-570, 1992.
Arias, I.M. et al., "Structure & Function of P-Glycoprotein in the Normal Liver", Xenobiotics and Cancer (L. Ernster et al., eds.), Japan Sci. Soc. Press, Tokyo/Taylor & Francis, Ltd., London, pp. 229-239, 1991.
Akitoshi et al., Abstract "Acceleration of Transdermal Absorption of Pharmaceuticals by Essential Oils and Organic Solvents", Chem Abst., 112:125228t, 1990.
Baciewicz et al., "Ketoconazole and Fluconazole Drug Interactions", Archives of Internal Medicine, 153(17):1970-76, 1993.
Back et al., "Comparative Effects of two Antimycotic Agents, Ketoconazole and Terbinafine on the Metabolism of Tolbutamide, Ethinyloestradiol, Cyclosporin and Ethoxycoumarin by Human Liver Microsomes In Vitro", British Journal of Clinical Pharmacology, 28:166-170, 1989.
Back et al., "Azoles, Allylamines and Drug Metabolism", British Journal of Dermatology, Supplement 39, 126:14-18, 1992.
Back, David J., and Orme, Michael L'E.; "Pharmacokinetic Drug Interactions with Oral Contraceptives", (1990) Clin. Pharmacokinet. 18(6):472-484.
Callaghan, Richard and Riordan, John R.; "Synthetic and Natural Opiates Interact with P-glycoprotein in Multidrug-resistant Cells", (1993) J. Biol. Chem. 268 (21) :16059-16064.
Chan et al., "Drug Interactions with Cyclosporine: Focus on Antimicrobial Agents", Clinical Transplantation, 6: (3) (1) :141-153, Jun. 1992.
Chang, Tammy et al., "The Effect of Water-Soluble Vitamin E on Cyclosporine Pharmacokinetics in healthy Volunteers", Abstract in American Society to Clinical Pharmacology and Therapeutics, 57 (2) :163, Feb 1995.
Clynes, Martin; "Cellular Models for Multiple Drug Resistance in Cancer", (1993) In Vitro Cell. Dev. Biol. 29A:171-179.
de Smet et al., "Combined use of Cyclosporine and Ketoconazole in the treatment of Endogenous Uveitis", American Journal of Ophthalmology, 113:687-690, Jun. 1992.
Endicott, Jane A., and Ling, Victor; "The Biochemistry of P-glycoprotein-mediated Multidrug Resistance", (1989) Annu. Rev. Biochem. 58:137-171.
Fahr, Alfred; "Cyclosporin Clinical Pharmacokinetics", (1993) Clin. Pharmacokinetic 24 (6) :472-495.
Fairchild, Craig R., and Cowan, Kenneth H.; "Keynote Address: Multidrug Resistance: A Pleiotropic Response To Cytotoxic Drugs" (1991) Int. J. Radiation Oncology Biol. Phys. 20:361-367.
Fasco, Michael J. et al.; "Rat Small Intestinal Cytochromes P450 Probed by Warfarin Metabolism" (1993) Mol. Pharmacol. 43:226-233.
First et al., "Concomitant Administration of Cyclosporin and Ketoconazole in Renal Transplant Recipients", The Lancet, 2:1198-1201, Nov. 18, 1989.
First et al., "Cyclosporine Dose Reduction by Ketoconazole Administration in Renal Transplant Recipients", Transplantation, 51 (2): 365 -370, Feb. 1991.
Fojo, Antonio T.; "Multidrug Resistance" (1991) Adv. Intern. Med. 36:195-218.
Gatmaitan, Zenaida C. and Irwin M. Arias; "Structure and Function of P-Glycoprotein in Normal Liver and Small Intestine" (1993) Adv. Pharmacol. 24: 77-97.
Greenblatt. David J.; "Presystemic Extraction: Mechanisms and Consequences"(1993) J. Clin. Pharmacol 33: 650-656.
Hebert, Mary F. et al.; "Bioavailability of Cyclosporine with Concomitant Rifampin Administration is Markedly Less Than Predicted by Hepatic Enzyme Induction" (1992) Clin. Pharmacol. Ther. 52:453-457.
Henricsson et al., "Cyclosporin Metabolism in Human Liver Microsomes and its Inhibition by Other Drugs", Pharmacology & Toxicology, 66:49-52, 1990.
Hunter, J. et al., "Epithelial Secretion of Vinblastine by Human Intestinal Adenocarcinoma Cell (HCT-8 and T84) Layers Expressing P-Glycoprotein", British Journal of Cancer, 64:437-444, 1991.
Hunter, Janice et al.; "Functional Expression of P-glycoprotein in Apical Membranes of Human Intestinal Caco-2 Cells", (1993) J. Biol Chem. 268:14991-14997.
Jancis, Erik M. et al.; "Estradiol Induction of Rhodamine 123 Efflux and the Multidrug Resistance Pump in Rat Pituitary Tumor Cells" (1993) Mol. Pharmacol. 43:51-56.
Kaminsky, Laurence, and Michael J Fasco; "Small Intestinal Cytochromes P450" (1992) Toxicology 21 (6):407-422.
Kolars, Joseph C. et al.; "Identificat
Benet Leslie Z.
Benet Reed M.
Wacher Vincent J.
AvMax, Inc.
Page Thurman K.
Spear James M.
LandOfFree
Use of essential oils to increase bioavailability of oral pharma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of essential oils to increase bioavailability of oral pharma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of essential oils to increase bioavailability of oral pharma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-67804